ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial

NCT00839826 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

641

Enrollment

INDUSTRY

Sponsor class

Conditions

Thromboembolism
Prevention

Interventions

DRUG: Rivaroxaban (BAY59-7939)
DRUG: Enoxaparin

Sponsor

Bayer